SS Innovations International (NASDAQ: SSII) has expanded its global presence with the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company's SSi Mantra 3.0 surgical robotic system. The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video, which noted that Kings Hospital has already completed more than 25 robotic procedures in just three weeks.
The introduction of robotic cardiac surgery in Sri Lanka represents a significant advancement for the country's healthcare sector, potentially improving surgical precision, reducing recovery times, and expanding access to minimally invasive cardiac interventions. For SS Innovations, this milestone underscores the versatility and clinical acceptance of the SSi Mantra system in a new market and specialty. The company reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, demonstrating a rapidly growing installed base.
Financially, SS Innovations' second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures indicate rising utilization of the company's installed systems, which is critical for recurring revenue streams and long-term profitability. The successful launch in Sri Lanka not only validates the SSi Mantra's performance in cardiac procedures but also positions SS Innovations as a key player in the global robotic surgery market, challenging established competitors.
The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to the world's largest healthcare markets, significantly amplifying the company's growth potential. The Sri Lanka program serves as a proof point for the system's safety and efficacy, which could support regulatory submissions and accelerate adoption in other regions.
Forward-looking statements in the article highlight inherent risks and uncertainties that could affect actual results, including factors beyond management's control. Investors are cautioned not to place undue reliance on these statements. For more information, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at https://IBN.ai/Disclaimer. The original release can be viewed at www.newmediawire.com.
